Evidence map›Paper›PMID 38785546›Full record

ArticleCurrent issues in molecular biology2024

Ye-Rin Woo, Chan-Seong Kwon, Ji-Eun Lee, Byeol-Eun Jeon, Tae-Jin Kim, Joy Choo, Young-Seob Seo, Sang-Woo Kim

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Norchelerythrine fromInternational journal of oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ye-Rin WooDepartment of Integrated Biological Science, College of Natural Sciences, Pusan National University, Busan 46241, Republic of Korea.
Chan-Seong KwonDepartment of Integrated Biological Science, College of Natural Sciences, Pusan National University, Busan 46241, Republic of Korea.
Ji-Eun LeeDepartment of Integrated Biological Science, College of Natural Sciences, Pusan National University, Busan 46241, Republic of Korea.
Byeol-Eun JeonDepartment of Integrated Biological Science, College of Natural Sciences, Pusan National University, Busan 46241, Republic of Korea.
Tae-Jin KimDepartment of Integrated Biological Science, College of Natural Sciences, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0001-7678-0478
Joy ChooDepartment of Biological Sciences, College of Arts and Sciences, Texas Tech University, Lubbock, TX 79409, USA.
Young-Seob SeoKorea Research Institute of Standard and Science, Daejeon 34113, Republic of Korea.ORCID 0000-0001-5233-4422
Sang-Woo KimDepartment of Integrated Biological Science, College of Natural Sciences, Pusan National University, Busan 46241, Republic of Korea.

Funding

National Research Foundation (NRF), Republic of Korea 2020R1I1A2075060 and 2022R1A4A5031503
6 · The paper itself

Abstract

The proto-oncogene MYC is frequently dysregulated in patients with diffuse large B-cell lymphoma (DLBCL) and plays a critical role in disease progression. To improve the clinical outcomes of patients with DLBCL, the development of strategies to target MYC is crucial. The use of medicinal plants for developing anticancer drugs has garnered considerable attention owing to their diverse mechanisms of action. In this study, 100 plant extracts of flora from the Republic of Korea were screened to search for novel agents with anti-DLBCL effects. Among them,

Indexed as

Ajania pacifica (Nakai) K. Bremer and Humphriesanti-cancer activitiesB-cell lymphomaMYC expression

Identifiers

PMID38785546
PMCPMC11119827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.